Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Lava Therapeutics B.v. (LVTX)

Sector - Healthcare

Price chart

-17.27%
Return from IPO

Company News

IPO Profile

About company

They are a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Their approach activates Vg9Vd2 T cells, a specific and relatively abundant gamma-delta effector T cell subset, upon cross-linking to a selected tumor target by their bispecific gamma-delta T cell engagers, or gamma-delta bsTCEs. These cells have the natural ability to distinguish tumor cells from healthy cells by sensing certain intracellular metabolites that are enriched in cancer cells. Activated Vg9Vd2 T cells are engaged for direct tumor cell killing and, in addition, orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor microenvironment. Their preclinical data demonstrate that Vg9Vd2 T cell activation and killing of patient-derived tumor cells by their gamma-delta bsTCEs is potent and specific thereby providing a significant opportunity to address unmet medical needs, if approved. They expect that activation of adaptive immunity by their approach has the potential to provide durable immune responses with the potential of enhancing patient survival. They believe they are the only company developing bispecific gamma-delta T cell engaging antibodies for the treatment of cancer.
Industry
Pharmaceutical Preparations
CEO CFO
Stephen Hurly Edward F. Smith
Employees Founded
31 2016

Contacts

Address: Yalelaan 60 3584 Cm Utrecht, The Netherlands

Telephone: +31 6 3000 3035

Web page: http://www.lavatherapeutics.com

IPO information

First Trade Date 3/25/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 6.7
Shares Revised (MM) 6.7
Expected offer amount (MM) $100.5
Realized offer amount(MM) $100.5

Financial Data (last reporting year)

Market Cap (MM) $380.3
Revenues (MM) $3.1
Net Income (Loss) (MM) $-13.9

Voting

What do you think will happen with the LVTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
JP Morgan/ Jefferies/ SVB Leerink
CO-Managers
Kempen

Sector: Healthcare

Tweets about $LVTX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats